Hikma Pharmaceuticals (HKMPF) Upgraded to Buy at ValuEngine

Hikma Pharmaceuticals (OTCMKTS:HKMPF) was upgraded by ValuEngine from a “hold” rating to a “buy” rating in a research note issued on Saturday.

A number of other research analysts have also weighed in on HKMPF. Jefferies Group lowered Hikma Pharmaceuticals from a “hold” rating to an “underperform” rating in a research report on Wednesday. Zacks Investment Research upgraded Hikma Pharmaceuticals from a “strong sell” rating to a “hold” rating in a research report on Tuesday, October 31st. Three research analysts have rated the stock with a sell rating, three have issued a hold rating and one has assigned a buy rating to the company’s stock. The stock presently has a consensus rating of “Hold”.

Shares of Hikma Pharmaceuticals (OTCMKTS HKMPF) traded down $1.04 during trading on Friday, hitting $14.06. The stock had a trading volume of 600 shares, compared to its average volume of 17. Hikma Pharmaceuticals has a 52-week low of $12.40 and a 52-week high of $27.50.

WARNING: This news story was first reported by American Banking News and is the property of of American Banking News. If you are reading this news story on another site, it was illegally copied and reposted in violation of US and international trademark & copyright laws. The correct version of this news story can be viewed at https://www.americanbankingnews.com/2018/01/13/hikma-pharmaceuticals-hkmpf-upgraded-to-buy-at-valuengine.html.

Hikma Pharmaceuticals Company Profile

Hikma Pharmaceuticals PLC develops, manufactures, and markets a range of generic, branded, and in-licensed pharmaceutical products in solid, semi-solid, liquid, and injectable final dosage forms worldwide. It operates through three segments: Branded, Injectables, and Generic. The Branded segment offers 377 products in 1,125 dosage forms and strengths in the anti-infective, cardiovascular, diabetes, central nervous system (CNS), gastro-intestinal, oncology, respiratory, and miscellaneous therapeutic areas.

To view ValuEngine’s full report, visit ValuEngine’s official website.

Receive News & Ratings for Hikma Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hikma Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply